A Plenary Session of the 1998 American Urological Association annual meeting in San Diego focused on the continuing debate on whether screening for prostate cancer reduces prostate cancer mortality. Presenting the argument for screening was Dr David Woods from Wayne State University, Detroit, Michigan, USA and opposing him was Dr Steven Woolf from Medical College of Virginia, Virginia, USA. The moderator in the debate was Dr Ian Thompson from Brooke Army Medical Center, Texas, USA.
In his opening presentation, Dr Thompson focused on the discrepancies that exist in the US regarding the recommendations on screening for prostate cancer. The American Cancer Society's recommendation includes annual digital rectal examination (DRE) and prostate-speci®c antigen (PSA) measurement in men 50 y of age and over who have a 10 y life expectancy. In contrast, the National Cancer Institute and the US Preventive Screening Task Force make no recommendations on screening.
Dr Thompson questioned why this confusion should exist. He con®rmed that prostate cancer is a very serious disease, with 180 000 cases diagnosed and 39 000 deaths estimated to occur in the US in 1998. Early detection and subsequent treatment is expensive, however. The PSA assay is a highly sensitive test that will detect the disease at an early stage, although there is no conclusive scienti®c evidence that indicates screening increases life expectancy.
Three questions were posed to each of the debaters: The fact is that PSA is not detecting predominantly autopsy tumours, but instead the majority of tumours identi®ed at radical prostatectomy are clinically signi®cant, that is they can result in the death of the patient. The Detroit SEER data indicate that during the period 1991±1995, there was a 6.2% decline in prostate cancer mortality. Data from the Olmsted County study presented by Dr R Roberts at the AUA meeting indicate that with PSA testing the incidence of prostate cancer and associated mortality peaked in 1991±1992, but both parameters have declined in recent years (Roberts RO et al, J Urol 1998; 159: 474A). Incidence rates still remain above the pre-PSA rates, while mortality rates have shown a steady decline in the last 5 y to a level below the pre-PSA rates ( Figure. 1 ). These ®ndings suggest that increased screening for prostate cancer may have a bene®cial effect on community mortality from prostate cancer.
Further improvement in outcome could be gained by:
prostate cancer prevention improved treatment of metastatic disease early detection and effective treatment
At present, prevention of prostate cancer is not a feasible option and treatment for metastatic disease is the same as 40 y ago. However, outcomes have improved with the early detection of the disease and re®ned treatment. Since the introduction of PSA testing, the percentage of patients with clinically localised disease now represents 78% of all new cases of prostate cancer. Only 3% of men will have metastatic disease at the time of diagnosis. In addition, re®nements to the radical prostatectomy procedure have resulted in improved morbidity and mortality rates. Technological advances in radiation therapy have also allowed higher doses of radiation to be given more safely.
Dr Wood discussed the complications associated with radical prostatectomy and their changing pattern in recent years. Since 1994, there has been a reduction in the rate of major complications, while minor complications have remained the same during the period 1991± 1997. One of the major problems relating to this procedure is post-operative continence. Data on the percentage of dry patients after the operation varies, with 37% being recorded in a Medicare survey (Fowler FJ et al, Urology 1993; 42: 622) and 94% from an academic series (Eastman P et al, J Urol 1996; 156: 1707). It should be noted that the Medicare survey was conducted during 1988±1990, prior to the use of PSA testing; in addition, only men over 65 y of age were evaluated.
Dr Wood pointed out that urinary dysfunction has a relatively low impact on quality of life and that, overall, radical prostatectomy resulted in greater bene®t than harm. He concluded by stating that although there are no randomised clinical studies showing that PSA screening for prostate cancer reduces mortality rate, PSA screening does have a positive role in detecting clinically signi®cant cancers. PSA testing and DRE should be offered annually, starting at age 50 y in men who have at least a 10 y life expectancy and in younger men who are at high risk. By diagnosing prostate cancer early and aggressively treating the disease we can aim to decrease death rates further.
Dr S Woolf: The argument against screening
Dr Woolf agreed that prostate cancer is a serious disease with a high burden of suffering and he also acknowledged that PSA testing does detect clinically signi®cant tumours. This is only the tip of iceberg, however, as the majority of men (over 9 million in the US) have microscopic prostate cancer that will not develop and will not result in death. Risk factors for progression of the disease include tumour grade, cell differentiation, tumour volume and disease stage.
On the question of whether early detection can prolong life and reduce morbidity, there are currently no randomised clinical trials demonstrating the bene®ts of early detection. Indirect evidence for the bene®ts of early detection come from the fact that PSA detects early stage disease, which has a higher 5 y survival rate. However, 5 y survival rates should not be used as the basis for bene®ts of PSA screening. Despite this shift in staging with PSA screening, it is unclear whether the improved survival observed is due to lead-time bias rather than an actual improvement in outcome. Lead-time bias can occur when survival appears to be lengthened because the diagnosis was made earlier, rather than because death was delayed. It should also be noted that the lack of effective treatment will nullify the bene®ts of early cancer detection.
Controlled trials examining the effectiveness of screening for a range of other cancers show improvements in mortality rates for breast, colorectal and cervical cancer. In the case of prostate cancer, lung, pancreatic and ovarian cancer, mortality bene®ts from screening are unproven. In addition, data from (Johansson et al, JAMA 1997; 277: 467± 471) indicate that deferred treatment of localised prostate cancer is associated with a 10 y survival rate of 87% and a 15 y survival rate of 81%.
Dr Woolf spoke of the harms of screening. Falsepositive PSA results due to benign prostatic hyperplasia or prostatitis have been recorded in 32±40% of men tested. Such results lead to anxiety for the patient and unnecessary follow-up testing with repeat PSA and possibly prostate needle biopsy. A more serious concern of testing is the potential complications of treatment, such as erectile dysfunction, incontinence and death.
Ultimately, the most important question about PSA screening is whether it improves the overall health and well-being of patients. Decision analysis has been used to estimate the net effect of bene®ts and risks on qualityadjusted survival. Results suggest that there is a net loss in quality-adjusted survival with PSA screening.
In conclusion, Dr Woolf stated that not all men should be screened. Instead, clinicians should look at individual cases and determine the best treatment options for that patient based on their condition. He would not recommend PSA screening for men under 50 y of age and in those with a life expectancy of less than 10 y. Instead, the option for screening should be given to patients 50±70 y of age after they have been provided with the relevant information.
Conclusions
In his summary of the debate, Dr Thompson addressed new data generated from the Quebec Screening Study. A 7 y follow-up of men with prostate cancer indicated 137 deaths from prostate cancer in 38 056 men who were not screened for the disease and 5 deaths in 8137 men who were screened. This translates into a 3.2-fold increase in mortality in unscreened men. However, there was a great deal of cross-over between the two groups and a reanalysis of the data taking this in to account indicated an increased mortality of just 1.1 in unscreened men.
Other trials being conducted to examine the bene®ts of PSA screening include:
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Study European Randomised Study of Prostate Cancer Screening Prostatectomy Intervention Versus Observation Trial (PIVOT) The PLCO and European studies will test whether there is a survival advantage to screening, while PIVOT will assess the bene®ts of treatment over observation. Dr Thompson concluded that, in 20 y time, we will have better data on prostate screening, but it will still remain the personal decision of the patient as to when to begin early detection.
